טופסיטיניב טבע 5 מ"ג
TOFACITINIB TEVA 5 MG

פעילות רפואית

Rheumatoid arthritis: Tofacitinib Teva 5 MG in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.
Psoriatic arthritis: Tofacitinib Teva 5 MG in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adultpatients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy.
Ulcerative colitis: Tofacitinib Teva 5 MG is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Ankylosing spondylitis: Tofacitinib Teva 5 MG is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.
Juvenile idiopathic arthritis (JIA): Tofacitinib Teva 5 MG is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs). Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate